Is AST a better monitoring choice than ALT on cagrilintide?

The specifics, since they change the answer: AST · ALT · cagrilintide.

The comparison I want does not seem to exist anywhere in a form I can evaluate.

I have read the arguments for each and they do not engage with each other.

Which axes does this decision turn on?

This is answerable, and the answer is mostly about which tests rather than how many.

A twenty-analyte panel run on a healthy person will produce, on average, one out-of-range result purely from how reference intervals are constructed. That is arithmetic rather than pathology.

Delta checks — comparing against your own previous value — are far more sensitive than comparing against a population interval, which is the argument for keeping a series rather than a snapshot.

The caveat is that a panel is not a diagnosis and interpreting one is a clinician's job, particularly when several values move together.

One out-of-range value on a twenty-analyte panel is expected. Two on a repeat is a finding.

Answer first: decide what you would do differently for each possible result before you order the panel. Anything that fails that test is a number you will worry about and not act on.

Timing matters per analyte: cortisol and testosterone are diurnal, triglycerides are postprandial, and creatinine responds to hydration and to recent training. Fixing the conditions removes most of the noise.

To be exact about it, haemolysis in the sample raises potassium and several enzymes spuriously. If a result is bizarre, ask whether the sample was flagged before building a theory on it.

Pre-analytical factors — posture, tourniquet time, fasting, sample handling — are the largest source of error in routine biochemistry, well ahead of the analysis itself.

Nothing here is medical advice. If something is out of range and you do not know why, that is a consultation rather than a research project.

Keep the full report, not the number. You will need the units and the interval later.

The honest position is that most people order too many analytes and too few time points, when the reverse would be more informative.

Repeat before you react. A single abnormal value has a substantial probability of being within the combined biological and analytical variation of a normal one.

External quality assurance schemes document between-laboratory differences on common analytes that routinely exceed the size of clinically interesting changes.

Ordering tests you will not act on generates anxiety and incidental findings, both of which have costs.

Decide the action for each result before you order the test.

edited 14 Nov 2025 by haze_check — added the citation requested in comments

Answering this needs to distinguish screening from monitoring. A screening panel looks for the unexpected; a monitoring panel tracks something you already have a reason to watch.

Keep the reports rather than the numbers. Units, reference intervals and methods all vary, and a bare number two years later is not comparable to anything.

Biological variation data are published per analyte and are the basis for the reference change value — the difference between two results that is larger than noise.

Baseline first, then a repeat under identical conditions. Everything else is secondary.

edited 29 Oct 2025 by s_kalniete — corrected a unit error in the worked example